Jun 11, 2020
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
May 29, 2020
Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings
Apr 08, 2020
Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9
Feb 14, 2020
European Biosimilar Insulin Glargine & Lispro Market Analysis, 2014-2024 - Growing Concerns Regarding the Cost of Insulin Treatment Spurs Demand
Dec 04, 2019
Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
Nov 04, 2019
Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
Jun 05, 2019
Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus®
Dec 13, 2018
Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mar 27, 2018
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee(TM), Biosimilar Insulin Glargine
Jan 29, 2018
Mylan and Biocon Receive Positive CHMP Opinion for Semglee(TM), Biosimilar Insulin Glargine
Dec 14, 2017
Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents
Sep 14, 2017
Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice
Sep 12, 2017
Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL
Aug 02, 2017
BasalogOne(TM): New Diabetes Solution From Abdi Ibrahim Pharmaceuticals & Biocon Limited
Jun 10, 2017
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions
Jun 10, 2017
New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent
Jun 10, 2017
In Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk